Abstract

More pharmaceutical companies are utilizing the stereochemistry of racemic mixtures as a new method of drug discovery, which make up about 25% of agents on the market.  Levalbuterol, the R-enantiomer of albuterol, is now marketed for treatment of asthma in the United States with the claim of a lower incidence of cardiac side effects. This study aims to examine the impact of each agent on cardiovascular vital signs.

Keywords

Levalbuterol, racemic albuterol, tachycardia, R-albuterol

Cite This Article

Mondin, J. J., Cottingham, L. G., & Ratliff, P. D. (2015). Clinical Impact of Levalbuterol versus Racemic Albuterol on Cardiovascular Vital Signs in Patients with Asthma and Chronic Obstructive Pulmonary Disease (COPD), International Journal for Pharmaceutical Research Scholars (IJPRS), 4(4), 63-68.